Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » In Silico: Mar 1, 2002

In Silico: Mar 1, 2002

Mar 01, 2002
Premium

www.GenomeWeb.COM Daily

 

“The market is rewarding profitability, not upside value. … When there is [an IPO] window, we are prepared to go through it.”

— Cellomics President and CEO D. Lansing Taylor, on laying off 50 employees and the company’s IPO potential

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Keep It (Partly) Virtual

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

For Cross-Protection

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Proteomics of Severity

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Genome Biology Papers on Regulatory Element, Single-Cell Integration, Sequence Simulation Tools

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.